ceem-22-403.pdf

by

Submission date: 17-May-2023 10:06AM (UTC+0700) Submission ID: 2095116211 File name: ceem-22-403.pdf (1.68M) Word count: 5467 Character count: 29122 Journal Pre-proofs

This PDF file is not yet the definitive version. This version will undergo additional editing and correction before it is published in its final form.

Systematic Review

Received: 2022/11/25 Revised: 2023/03/19 Accepted: 2023/03/29

DOI: https://doi.org/10.15441/ceem.22.403

The impact of COVID-19 on mortality in trauma patients undergoing orthopedic surgery: a

systematic review and meta-analysis

Abbreviated title: Orthopedic trauma surgery

Husna Dharma Putera¹, Valentina Halim², Roselina Panghiyangani³

¹Department of Orthopedic and Traumatology, Faculty of Medicine, Ulin General Hospital, Universitas

Lambung Mangkurat, Banjarmasin, Indonesia

²Siloam Hospital, Banjarmasin, Indonesia

³Biomedical Department, Faculty of Medicine, Universitas Lambung Mangkurat, Banjarmasin, Indonesia

Correspondence to: Husna Dharma Putera

Department of Orthopedic and Traumatology, Faculty of Medicine, Ulin General Hospital, Universitas

Lambung Mangkurat, 43 Jalan Ahmad Yani, Banjarmasin 70233, Indonesia

Email: hdputera@ulm.ac.id

ABSTRACT

Objective: The global spread of the COVID-19 pandemic has affected all aspects, including orthopedic trauma surgery. This study aims to investigate whether COVID-19–positive patients who underwent orthopedic surgery trauma had a higher risk of postoperative mortality.

Methods: ScienceDirect, the Cochrane COVID-19 Study Register, and MEDLINE were searched for original publications. This study adhered to the PPRISMA 2020 statement. The validity was evaluated using a checklist developed by the Joanna Briggs Institute. Study and participant characteristics, as well as the odds ratio, were extracted from selected publications. Data were analyzed using RevMan ver. 5.4.1.

Results: After applying the inclusion and exclusion criteria, 16 articles among 717 total were deemed eligible for analysis. Lower-extremity injuries were the most common condition, and pelvic surgery was the most frequently performed intervention. There were 456 COVID-19–positive patients (6.12%) and 134 deaths among COVID-19–positive patients, revealing a mortality escalation (29.38% vs. 5.30% among COVID-19–negative patients; odds ratio, 7.72; 95% confidence interval, 6.01–9.93; P<0.00001). **Conclusion:** Among COVID-19–positive patients, the postoperative death rate increased by 7.72 times. It may be possible to improve prognostic stratification and perioperative care by identifying risk factors.

Keywords: Wounds and injuries; Orthopedic procedures; COVID-19; Mortality

CAPSULE SUMMARY

What is already known

During the COVID-19 pandemic, there was a decrease in emergency room visits for trauma and surgical intervention, particularly in traumatology services.

What is new in the current study

This study analyzes the most recent literature on postoperative mortality in trauma patients undergoing orthopedic surgery during the COVID-19 pandemic.

INTRODUCTION

The World Health Organization (WHO) announced the discovery of a new condition, COVID-19, in early February 2020, before declaring a global pandemic in March 2020. The rapid global spread of the causative pathogen, SARS-CoV-2, has caused major changes to human life worldwide. Many countries in the Asia-Pacific region, including Australia, Korea, and Japan, were among the first to respond to the COVID-19 epidemic [1].

During the COVID-19 pandemic, emergency room visits decreased, particularly visits for trauma and surgical intervention in traumatology cases [2,3]. With this reduction in visits, patients more frequently received delayed care during the current pandemic [4]. Previous studies have shown that delaying surgery increases mortality and the risk of postoperative pneumonia in trauma patients [5].

The present study sought to conduct a systematic review and meta-analysis on postoperative mortality in COVID-19–positive and –negative patients undergoing orthopedic trauma surgery. The present meta-analysis sought to investigate the odds ratio (OR) of mortality in this patient population by comparing statistics between COVID-19–positive and –negative groups. We speculated that postoperative COVID-19–positive orthopedic trauma patients would have a higher risk of death than those negative for COVID-19.

METHODS

Search strategy and study selection

The protocol of this review was registered in PROSPERO (International Prospective Register of Systematic Reviews) on September 27, 2022 (No. CRD42022359112). In accordance with recent PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) 2020 statement for identifying research through databases and registers, a systematic review of the mortality in orthopedic surgery owing to trauma during the COVID-19 pandemic was performed, as shown in Fig. 1 [6]. The phrases "orthopedic" AND "trauma" AND "surgery" AND "COVID-19" were used to search the ScienceDirect and MEDLINE (via PubMed) databases for English-language studies that reported mortality among both COVID-19–positive and –negative patients. The literature search was conducted on September 20, 2022. A search using MeSH (Medical Subject Headings) terms was carried out

whenever possible using the combination of the search 1 ("orthopedic trauma surgery" [MeSH Terms] OR "orthopedic trauma surgery" [All Fields]) AND search 2 ("COVID-19 [MeSH Terms] OR "COVID-19" [All Fields]) strategies.

Inclusion and exclusion criteria

We included observational studies like cohort, cross-sectional, and case–control studies but excluded review articles. The validity of the papers included in this study was evaluated using a series of inquiries based on a checklist in line with the kind of study created by the Joanna Briggs Institute [7,8], as shown in Supplementary Table 1 [9–23] and Supplementary Table 2 [24]. Articles that did not fit the requirements for inclusion were rejected. The inclusion criteria formulated according to the PICO mnemonic for clinical research questions were as follows: (1) P (patient, population, problem): patients of all ages who underwent orthopedic trauma surgery; (2) I (intervention, prognostic factor, or exposure): COVID-19 infection (positive or negative polymerase chain reaction result); (3) C (comparison or intervention): none; and (4) O (outcome): postoperative mortality.

Data synthesis

If possible, the data synthesis included information on patient mean age, sex, death rate, underlying disease, complications, intervention site, type of surgery, and hospital stay. The data were summarized in Microsoft Excel (Microsoft Corp) after their collection, and RevMan ver. 5.4.1 (Cochrane Collaboration) was used for statistical analysis. We performed planned subgroup analyses for the confounding variables, which included time points of patient outcome measurement (inpatient vs. 30-day follow-up) and age (<60 years vs. >60 years). Publication bias was measured by visual inspection of funnel plots and quantitatively using Egger test [25]. We considered findings significant if P<0.05. GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) scores were used to evaluate the certainty of the evidence for each outcome [26]. A GRADE summary of the findings in Table 3 was generated using GRADEpro (GradePro Inc) [27].

RESULTS

During the literature search, 717 studies were discovered. After removing duplicates, 691 studies remained, and 32 potentially relevant studies were chosen for eligibility examination. This metaanalysis included 16 observational studies (10 retrospective cohort studies, five prospective cohort studies, and one cross-sectional study). The majority of patients in these investigations were >60 years old. The study characteristics and postoperative mortality findings are shown in Table 1 [9–24]. The most common injury sites were the hip and femur, followed by other lower-limb sites such as the patella, tibia, ankle, foot, and upper limb. Supplementary Table 3 shows the types of injuries that required orthopedic surgery. Hemiarthroplasty, total hip arthroplasty, unspecified elective minor surgery, and open reduction and internal fixation of the femur were the major surgeries performed.

Five studies [15,18,20,21,24] compared the number of orthopedic surgeries performed during and before the start of the COVID-19 pandemic and discovered that the numbers of surgeries performed did not significantly differ. Nonetheless, postoperative mortality increased significantly during the pandemic.

During the COVID-19 pandemic, 7,795 injuries were reported (Supplementary Table 3), with 15 cases (0.19%) not being treated surgically. According to Table 1 [9–24], we identified 6,996 COVID-19–negative patients (93.89%) and 456 COVID-19–positive patients (6.11%) among the 7,452 operative patients who underwent COVID-19 testing via polymerase chain reaction testing of a nasopharyngeal swab. Meanwhile, 134 COVID-19–positive patients (29.38%) died after surgery compared to 5.30% of the COVID-19–negative group, despite the small number of COVID-19–positive patients. The mortality rate of COVID-19–positive patients ranged from 14.28% to 50% among included studies.

Complications due to COVID-19 were most commonly reported as the primary cause of postoperative death among COVID-19–positive patients. The reported primary causes of postoperative death, complications, underlying disease, and mean hospital stay in both groups are shown in Table 2 [9–24]. Eight studies [11–15,19,20,22] did not report the cause of death in their research.

A total of 1,616 reported surgeries from seven studies [13,16–18,20–22] are shown in Supplementary Table 4. In contrast, nine studies [9–12,14,15,19,23,24] did not specify the surgeries performed in their studies. Only Lim et al. [18] reported the type of anesthesia used in both groups.

Fig. 2 depicts the qualitative analysis of each study's funnel plot to determine the degree of asymmetry. Egger regression test was calculated with P=0.34. A funnel plot and Egger test showed no evidence of publication bias. As shown in Figs. 3–6 [9–24], we established a forest plot and subgroup analysis to illustrate the significance among all studies included in our meta-analysis. We analyzed the 16 trials and established a random-effects model, resulting in an overall OR of 7.72 (95% confidence interval [CI], 6.01–9.93; P<0.00001; I²=0%). As shown in Fig. 6[13–15,17,23], the incidence of venous thromboembolism (VTE) was increased among COVID-19–positive patients (OR, 4.08; 95% CI, 1.23–13.58). According to these findings, COVID-19 positivity might increase the mortality rate and occurrence of thromboembolism in patients undergoing orthopedic surgery.

The test for subgroup differences in Figs. 4 and 5 [9-24] indicated a statistically significant subgroup effect (P<0.05) at inpatient (OR, 8.67; 95% CI, 5.82–12.91), 30-day follow-up (OR, 7.32; 95% CI, 4.30–12.49), and in patients with a mean age of >60 years (OR, 7.75; 95% CI, 6.02–9.97). Mortality in COVID-19–positive patients with a mean age of <60 years showed an increase in one study, but this increase was not statistically significant (OR, 5.75; 95% CI, 0.46–72.30; P = 0.18).

DISCUSSION

This systematic review and meta-analysis looked at the death rate among COVID-19–positive and – negative trauma patients undergoing orthopedic surgery. Most of the participants in this study were >60 years old. This finding is consistent with those of Atinga et al. [28], who found that geriatric trauma cases are increasing every year and now account for >25% of all significant trauma cases in the United Kingdom. Aging is associated with progressive physiological changes that affect various systems. Elderly people respond to trauma in a physiologically different manner than other people. Physiological responses in the elderly might vary due to co-occurring diseases, premorbid frailty, and prescribed drugs.

Previous research has linked hip fracture in the elderly to greater morbidity, a loss of autonomy in activities of daily living, a high rate of institutionalization, and mortality. Conservatively, mortality

after hip fracture surgery is high in the first year, being approximately 30% of all cases [29–31]. In this study, 70 of the 134 patients with postoperative deaths among 456 COVID-19–positive patients who underwent orthopedic surgery had a hip or femur fracture.

According to Supplementary Table 4, the most commonly performed procedure in this study was hip arthroplasty. Haskel et al. [32] discovered that hip fracture volume in the elderly did not decrease during the lockdown period, even in areas severely affected by COVID-19 outbreaks. Age, a large waist circumference, a lower skeletal muscle index, bone mass density, vitamin D level, physical function, nutritional status, and cognitive function are linked to hip fractures in the elderly [33,34].

VTE involves both pulmonary embolism and deep vein thrombosis, respectively, and occurs in 0.6% to 1.5% of patients undergoing total joint arthroplasty. The risk factors for VTE are described by Virchow triad, which are venous stasis, endothelial damage, and a hypercoagulable state. VTE is typically the result of the interaction of two or less causes. Venous stasis can occur both during and after surgery due to intraoperative immobilization. Prolonged immobility raises the possibility of VTE development [35].

Previous research found that COVID-19–positive patients had a higher mortality rate during hip and femur fracture surgery [36–39]. Surgery within 48 hours does not correlate with a lower mortality rate in COVID-19–positive patients [13]. As shown in Table 2 [9–24], the mean hospital stay length among COVID-19–positive patients undergoing hip and femur surgery was longer than that among COVID-19–negative patients. This result is in line with the study by Kayani et al. [37], which stated that hip surgery in COVID-19–positive patients was associated with a longer hospital stay, longer immobilization, more hospitalizations in the intensive care unit, an increased chance of peri-operative complications, and greater mortality rates. COVID-19–positive patients with a smoking history and multiple (>3) significant comorbidities have a higher risk of death. Identifying factors that contribute to a higher death rate may improve prognostic classification and interdisciplinary perioperative care.

This review has some limitations. The majority GRADE rating in Table 3 was low because the evidence came from observational studies. Inaccurate studies with smaller sample sizes of COVID-19– positive patients may be influenced by chance. Of the 16 studies, only nine provided information about the type of surgery performed, eight reported the primary cause of postoperative death, and just one

provided information about the type of anesthesia used in both groups. All of the included studies were conducted prior to the availability of COVID-19 vaccines.

In conclusion, the postoperative mortality rate among COVID-19–positive patients was 7.72 times greater than that of COVID-19–negative patients. Identifying risk factors for increased mortality may improve prognostic classification and perioperative interdisciplinary medication. The findings of this study should be considered by the larger orthopedic community when developing guidelines for treating orthopedic trauma in specific populations in the COVID-19 era.

SUPPLEMENTARY MATERIALS

Supplementary Table 1. Joanna Briggs Institute risk of bias quality assessment for cohort studiesSupplementary Table 2. Joanna Briggs Institute risk of bias quality assessment for cross-sectional studies

Supplementary Table 3. Indications for orthopedic surgery during the COVID-19 pandemic Supplementary Table 4. The reported surgery in this study

Supplementary Material 1. PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) checklist.

Supplementary materials are available at https://doi.org/10.15441/ceem.22.403.

ETHICS STATEMENTS

Not applicable.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING

None.

AUTHOR CONTRIBUTIONS

Conceptualization: HDP; Formal analysis: VH, RP; Methodology: all authors; Project administration: HDP; Writing–original draft: HDP; Writing–review & editing: all authors. All authors read and approved the final manuscript.

ORCID

Husna Dharma Putera

Valentina Halim

https://orcid.org/0000-0002-5879-1242 Not available https://orcid.org/0000-0002-6233-1978

Roselina Panghiyangani

REFERENCES

- Kurozumi T, Minehara H, Kim JW, Oh CW, Miclau EE, Balogh ZJ. Orthopaedic trauma care during the early COVID-19 pandemic in the Asia-Pacific region. OTA Int 2021;4(1 Suppl):e119.
- Pamungkas KM, Dewi PI, Dyatmika IK, Maharjana MA, Meregawa PF. The impact of the COVID-19 pandemic on trauma cases in the orthopedics and traumatology services: a systematic review. J Kedokt Kesehat Indones 2022;13:68–78.
- 3. Nunez JH, Sallent A, Lakhani K, et al. Impact of the COVID-19 pandemic on an emergency traumatology service: experience at a tertiary trauma centre in Spain. Injury 2020;51:1414–8.
- Haleem A, Javaid M, Vaishya R, Vaish A. Effects of COVID-19 pandemic in the field of orthopaedics. J Clin Orthop Trauma 2020;11:498–9.
- Simunovic N, Devereaux PJ, Sprague S, et al. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ 2010;182:1609–16.
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
- JBI. Critical appraisal tools for use in JBI systematic reviews: checklist for cohort studies [Internet].
 JBI; 2020 [cited 2022 Sep DATE]. Available from: <u>https://jbi.global/critical-appraisal-tools</u>
- BI. Critical appraisal tools for use in JBI systematic reviews: checklist for analytical cross sectional studies [Internet]. JBI; 2020 [cited 2022 Sep DATE]. Available from: <u>https://jbi.global/critical-appraisal-tools</u>
- 9. Andrzejowski PA, Howard A, Vun JSH, et al. COVID-19: the first 30 days at a UK level 1 trauma centre and lessons learnt. Cureus 2020;12:e11547.
- Beaven A, Piper D, Plant C, Sharma A, Agrawal Y, Cooper G. Thirty-day mortality for proximal femoral fractures treated at a U.K. elective center with a site-streaming policy during the COVID-19 pandemic. JB JS Open Access 2021;6:e21.00009.
- Balakumar B, Nandra RS, Woffenden H, et al. Mortality risk of surgically managing orthopaedic trauma during the COVID-19 pandemic. Bone Jt Open 2021;2:330–6.
- 12. Clement ND, Hall AJ, Makaram NS, et al. IMPACT-Restart: the influence of COVID-19 on postoperative mortality and risk factors associated with SARS-CoV-2 infection after orthopaedic and

trauma surgery. Bone Joint J 2020;102-B:1774-81.

- Dallari D, Zagra L, Cimatti P, et al. Early mortality in hip fracture patients admitted during first wave of the COVID-19 pandemic in Northern Italy: a multicentre study. J Orthop Traumatol 2021;22:15.
- Egol KA, Konda SR, Bird ML, et al. Increased mortality and major complications in hip fracture care during the COVID-19 pandemic: a New York City perspective. J Orthop Trauma 2020;34:395– 402.
- 15. Fisher ND, Bi AS, Aggarwal V, Leucht P, Tejwani NC, McLaurin TM. A Level 1 Trauma Center's response to the COVID-19 pandemic in New York City: a qualitative and quantitative story. Eur J Orthop Surg Traumatol 2021;31:1451–6.
- Hall AJ, Clement ND, Farrow L, et al. IMPACT-Scot report on COVID-19 and hip fractures. Bone Joint J 2020;102-B:1219–28.
- LeBrun DG, Konnaris MA, Ghahramani GC, et al. Hip fracture outcomes during the COVID-19 pandemic: early results from New York. J Orthop Trauma 2020;34:403–10.
- Lim JA, Thahir A, Amar Korde V, Krkovic M. The impact of COVID-19 on neck of femur fracture care: a major trauma centre experience, United Kingdom. Arch Bone Jt Surg 2021;9:453–60.
- 19. Pass B, Vajna E, Knauf T, et al. COVID-19 and proximal femur fracture in older adults: a lethal combination?: an analysis of the registry for geriatric trauma (ATR-DGU). J Am Med Dir Assoc 2022;23:576–80.
- Sobti A, Memon K, Bhaskar RR, Unnithan A, Khaleel A. Outcome of trauma and orthopaedic surgery at a UK District General Hospital during the COVID-19 pandemic. J Clin Orthop Trauma 2020;11(Suppl 4):S442–5.
- 21. Thakrar A, Chui K, Kapoor A, Hambidge J. Thirty-day mortality rate of patients with hip fractures during the COVID-19 pandemic: a single centre prospective study in the United Kingdom. J Orthop Trauma 2020;34:e325–9.
- 22. Wright EV, Musbahi O, Singh A, Somashekar N, Huber CP, Wiik AV. Increased perioperative mortality for femoral neck fractures in patients with coronavirus disease 2019 (COVID-19): experience from the United Kingdom during the first wave of the pandemic. Patient Saf Surg

2021;15:8.

- 23. Zajonz D, Vaitl P, Edel M, et al. Effects of SARS-CoV-2 infections on inpatient mortality of geriatric patients after proximal femoral fracture surgery. Orthopadie (Heidelb) 2022;51:573–9.
- 24. Greensmith TS, Faulkner AC, Davies PS, et al. Hip fracture care during the 2020 COVID-19 firstwave: a review of the outcomes of hip fracture patients at a Scottish Major Trauma Centre. Surgeon 2021;19:e318–24.
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
- 26. Schunemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations [Internet]. The GRADE Working Group; 2013 [cited 2022 Sep DATE]. Available from: <u>https://guidelinedevelopment.org/handbook</u>
- 27. GRADEpro GDT: GRADEpro guideline development tool [software]. McMaster University and Evidence Prime; 2022. Available from: https://www.gradepro.org
- 28. Atinga A, Shekkeris A, Fertleman M, Batrick N, Kashef E, Dick E. Trauma in the elderly patient. Br J Radiol 2018;91:1087.
- 29. Civinini R, Paoli T, Cianferotti L, et al. Functional outcomes and mortality in geriatric and fragility hip fractures: results of an integrated, multidisciplinary model experienced by the "Florence hip fracture unit". Int Orthop 2019;43:187–92.
- Mariconda M, Costa GG, Cerbasi S, Recano P, Aitanti E, Gambacorta M, Misasi M. The determinants of mortality and morbidity during the year following fracture of the hip: a prospective study. Bone Joint J 2015;97-B:383–90.
- 31. Downey C, Kelly M, Quinlan JF. Changing trends in the mortality rate at 1-year post hip fracture: a systematic review. World J Orthop 2019;10:166–75.
- 32. Haskel JD, Lin CC, Kaplan DJ, et al. Hip fracture volume does not change at a New York City level
 1 trauma center during a period of social distancing. Geriatr Orthop Surg Rehabil
 2020;11:2151459320972674.
- 33. Liu LK, Lee WJ, Chen LY, et al. Association between frailty, osteoporosis, falls and hip fractures among community-dwelling people aged 50 years and older in Taiwan: results from I-Lan

Longitudinal Aging Study. PLoS One 2015;10:e0136968.

3

- 34. Steingrimsdottir L, Halldorsson TI, Siggeirsdottir K, et al. Hip fractures and bone mineral density in the elderly: importance of serum 25-hydroxyvitamin D. PLoS One 2014;9:e91122.
- 35. Santana DC, Emara AK, Orr MN, et al. An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020. Medicina (Kaunas) 2020;56:416.
- 36. Freitas T, Ibrahim A, Lourenco A, Chen-Xu J. Mortality in COVID-19 patients after proximal femur fracture surgery: a systematic review and meta-analysis. Hip Int 2022 Aug 12 [Epub]. https://doi.org/10.1177/11207000221116764
- 37. Kayani B, Onochie E, Patil V, et al. The effects of COVID-19 on perioperative morbidity and mortality in patients with hip fractures. Bone Joint J 2020;102-B:1136–45.
- 38. Levitt EB, Patch DA, Mabry S, et al. Association between COVID-19 and mortality in hip fracture surgery in the National COVID Cohort Collaborative (N3C): a retrospective cohort study. J Am Acad Orthop Surg Glob Res Rev 2022;6:e21.00282.
- Wang KC, Xiao R, Cheung ZB, Barbera JP, Forsh DA. Early mortality after hip fracture surgery in COVID-19 patients: a systematic review and meta-analysis. J Orthop 2020;22:584–91.






Fig. 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 statement flowchart of the search strategy and selection of studies.





	COVID-		COVID			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Andrzejowski et al	4	12	4	150	2.6%	18.25 [3.84, 86.67]	
Balakumar et al	19	43	11	146	8.5%	9.72 [4.11, 22.96]	
Beaven et al	9	40	8	145	5.9%	4.97 [1.78, 13.91]	
Clement et al	22	68	63	1501	19.6%	10.92 [6.19, 19.25]	
Dallari et al	8	53	7	424	5.6%	10.59 [3.67, 30.57]	
Egol et al	6	17	1	107	1.3%	57.82 [6.37, 525.04]	
Fisher et al	2	10	1	24	1.0%	5.75 [0.46, 72.30]	
Greensmith et al	2	5	5	84	1.6%	10.53 [1.42, 78.18]	
Hall et al	9	25	24	278	7.5%	5.95 [2.38, 14.90]	
LeBrun et al	3	7	1	40	1.0%	29.25 [2.43, 351.43]	
Lim et al	1	7	7	85	1.2%	1.86 [0.19, 17.69]	
Pass et al	32	123	214	3610	34.7%	5.58 [3.65, 8.54]	
Sobti et al	3	6	5	47	1.8%	8.40 [1.32, 53.40]	
Thakrar et al	4	12	1	6	1.0%	2.50 [0.21, 29.25]	
Wright et al	5	16	3	50	2.5%	7.12 [1.47, 34.39]	
Zajonz et al	5	12	16	299	4.0%	12.63 [3.61, 44.24]	
Total (95% CI)		456		6996	100.0%	7.72 [6.01, 9.93]	•
Total events	134		371				
Heterogeneity: Tau ² =	0.00; Chi	² = 13.8	7, df = 15	5(P = 0)	54); l² = (1%	
Test for overall effect							0.002 0.1 1 10 5 COVID-19 - COVID-19 +

010-01-

Fig. 3. Forest plot of all the articles included in this study. M-H, Mantel-Haenszel test; Random,

random-effects model; CI, confidence interval.

INPATIENT	COVID-	19 +	COVID	-19 -		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Andrzejowski et al	4	12	4	150	5.7%	18.25 [3.84, 86.67]	
Beaven et al	9	40	8	145	11.1%	4.97 [1.78, 13.91]	
Clement et al	22	68	63	1501	23.0%	10.92 [6.19, 19.25]	
Dallari et al	8	53	7	424	10.6%	10.59 [3.67, 30.57]	
Egol et al	6	17	1	107	3.0%	57.82 [6.37, 525.04]	
LeBrun et al	3	7	1	40	2.4%	29.25 [2.43, 351.43]	
Lim et al	1	7	7	85	2.9%	1.86 [0.19, 17.69]	
Pass et al	32	123	214	3610	28.8%	5.58 [3.65, 8.54]	-
Sobti et al	3	6	5	47	4.2%	8.40 [1.32, 53.40]	
Zajonz et al	5	12	16	299	8.2%	12.63 [3.61, 44.24]	
Total (95% CI)		345		6408	100.0%	8.67 [5.82, 12.91]	◆
			326				
Total events	93		320				
Heterogeneity: Tau ² =	= 0.10; Chi		1, df = 9	(P = 0.2	20); I ² = 27	%	
	= 0.10; Chi		1, df = 9	(P = 0.2	20); I ² = 27	%	0.002 0.1 1 10 50 COVID-19 - COVID-19 +
Heterogeneity: Tau ² = Test for overall effect	= 0.10; Chi : Z = 10.61	(P < 0.	1, df = 9 00001)	•	20); I ² = 27		COVID-19 - COVID-19 +
Heterogeneity: Tau ² = Test for overall effect 30-DAY	= 0.10; Chi : Z = 10.61 COVID-	(P < 0. 19 +	1, df = 9 00001) COVID-	.19 -		Odds Ratio	COVID-19 - COVID-19 + Odds Ratio
Heterogeneity: Tau ² = Test for overall effect 30-DAY Study or Subgroup	= 0.10; Chi Z = 10.61 COVID- Events	(P < 0.) 19 + Total	(1, df = 9 00001) COVID- Events	-19 - Total	Weight	Odds Ratio M-H, Random, 95% Cl	COVID-19 - COVID-19 +
Heterogeneity: Tau ² = Test for overall effect 30-DAY Study or Subgroup Balakumar et al	= 0.10; Chi : Z = 10.61 COVID- Events 19	(P < 0.) 19 + Total 43	(1, df = 9 00001) COVID Events 11	-19 - <u>Total</u> 146	Weight 38.5%	Odds Ratio M-H, Random, 95% CI 9.72 [4.11, 22.96]	COVID-19 - COVID-19 + Odds Ratio
Heterogeneity: Tau ² = Test for overall effect 30-DAY Study or Subgroup Balakumar et al Fisher et al	= 0.10; Chi : Z = 10.61 COVID- Events 19 2	(P < 0.) 19 + <u>Total</u> 43 10	COVID Events 11 11 1	-19 - Total 146 24	Weight 38.5% 4.4%	Odds Ratio M-H, Random, 95% CI 9.72 [4.11, 22.96] 5.75 [0.46, 72.30]	COVID-19 - COVID-19 + Odds Ratio
Heterogeneity: Tau ² = Test for overall effect 30-DAY <u>Study or Subgroup</u> Balakumar et al Fisher et al Greensmith et al	= 0.10; Chi : Z = 10.61 COVID- Events 19 2 2	(P < 0.) 19 + <u>Total</u> 43 10 5	COVID- Events 11 1 5	-19 - Total 146 24 84	Weight 38.5% 4.4% 7.1%	Odds Ratio M-H, Random, 95% Cl 9.72 [4.11, 22.96] 5.75 [0.46, 72.30] 10.53 [1.42, 78.18]	COVID-19 - COVID-19 + Odds Ratio
Heterogeneity: Tau ² = Test for overall effect 30-DAY Study or Subgroup Balakumar et al Fisher et al Greensmith et al Hall et al	= 0.10; Chi : Z = 10.61 Events 19 2 2 9	(P < 0.) 19 + <u>Total</u> 43 10 5 25	COVID- Events 11 1 5 24	-19 - Total 146 24 84 278	Weight 38.5% 4.4% 7.1% 33.8%	Odds Ratio M-H, Random, 95% Cl 9.72 [4.11, 22.96] 5.75 [0.46, 72.30] 10.53 [1.42, 78.18] 5.95 [2.38, 14.90]	COVID-19 - COVID-19 + Odds Ratio
Heterogeneity. Tau ² = Test for overall effect 30-DAY Study or Subgroup Balakumar et al Fisher et al Greensmith et al Hall et al Thakrar et al	= 0.10; Chi : Z = 10.61 Events 19 2 2 9 4	(P < 0. 19 + <u>Total</u> 43 10 5 25 12	COVID- Events 11 1 5 24 1	-19 - Total 146 24 84 278 6	Weight 38.5% 4.4% 7.1% 33.8% 4.7%	Odds Ratio M-H, Randorn, 95% CI 9.72 [4.11, 22.96] 5.75 [0.46, 72.30] 10.53 [1.42, 78.18] 5.95 [2.38, 14.90] 2.50 [0.21, 29.25]	COVID-19 - COVID-19 + Odds Ratio
Heterogeneity: Tau ² = Test for overall effect 30-DAY Study or Subgroup Balakumar et al Fisher et al Greensmith et al Hall et al	= 0.10; Chi : Z = 10.61 Events 19 2 2 9	(P < 0.) 19 + <u>Total</u> 43 10 5 25	COVID- Events 11 1 5 24	-19 - Total 146 24 84 278	Weight 38.5% 4.4% 7.1% 33.8%	Odds Ratio M-H, Random, 95% Cl 9.72 [4.11, 22.96] 5.75 [0.46, 72.30] 10.53 [1.42, 78.18] 5.95 [2.38, 14.90]	COVID-19 - COVID-19 + Odds Ratio
Heterogeneity. Tau ² = Test for overall effect 30-DAY Study or Subgroup Balakumar et al Fisher et al Greensmith et al Hall et al Thakrar et al	= 0.10; Chi : Z = 10.61 Events 19 2 2 9 4	(P < 0. 19 + <u>Total</u> 43 10 5 25 12	COVID- Events 11 1 5 24 1	-19 - Total 146 24 84 278 6	Weight 38.5% 4.4% 7.1% 33.8% 4.7% 11.5%	Odds Ratio M-H, Randorn, 95% CI 9.72 [4.11, 22.96] 5.75 [0.46, 72.30] 10.53 [1.42, 78.18] 5.95 [2.38, 14.90] 2.50 [0.21, 29.25]	COVID-19 - COVID-19 + Odds Ratio
Heterogeneity. Tau ² = Test for overall effect Study or Subgroup Balakumar et al Fisher et al Greensmith et al Hall et al Thakrar et al Avright et al	= 0.10; Chi : Z = 10.61 Events 19 2 2 9 4	(P < 0. 19 + Total 43 10 5 25 12 16	COVID- Events 11 1 5 24 1	-19 - Total 146 24 84 278 6 50	Weight 38.5% 4.4% 7.1% 33.8% 4.7% 11.5%	Odds Ratio M-H, Random, 95% Cl 9.72 [4.11, 22.96] 5.75 [0.46, 72.30] 10.53 [1.42, 78.18] 5.95 [2.38, 14.90] 2.50 [0.21, 29.25] 7.12 [1.47, 34.39]	COVID-19 - COVID-19 + Odds Ratio
Heterogeneity. Tau ² = Test for overall effect 30-DAY Study or Subgroup Balakumar et al Fisher et al Greensmith et al Hall et al Mright et al Total (95% CI)	= 0.10; Chi Z = 10.61 COVID- Events 19 2 2 9 4 5	(P < 0.) 19 + <u>Total</u> 43 10 5 25 12 16 111	COVID- Events 11 1 5 24 1 3 45	-19 - <u>Total</u> 146 24 84 278 6 50 588	Weight 38.5% 4.4% 7.1% 33.8% 4.7% 11.5% 100.0%	Odds Ratio M-H, Random, 95% CI 9.72 [4.11, 22.96] 5.75 [0.46, 72.30] 10.53 [1.42, 78.18] 5.95 [2.38, 14.90] 2.50 [0.21, 29.25] 7.12 [1.47, 34.38] 7.32 [4.30, 12.49]	COVID-19 - COVID-19 + Odds Ratio

Fig. 4. Postoperative mortality of (A) At inpatient and (B) 30-day follow-up. M-H, Mantel-Haenszel

test; Random, random-effects model; CI, confidence interval.

Riex

>60 YEARS	COVID-	19 +	COVID	19 -		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Andrzejowski et al	4	12	4	150	2.6%	18.25 [3.84, 86.67]			
Balakumar et al	19	43	11	146	8.6%	9.72 [4.11, 22.96]			
Beaven et al	9	40	8	145	6.0%	4.97 [1.78, 13.91]			
Clement et al	22	68	63	1501	19.8%	10.92 [6.19, 19.25]			
Dallari et al	8	53	7	424	5.7%	10.59 [3.67, 30.57]			
Egol et al	6	17	1	107	1.3%	57.82 [6.37, 525.04]			
Greensmith et al	2	5	5	84	1.6%	10.53 [1.42, 78.18]			
Hall et al	9	25	24	278	7.6%	5.95 [2.38, 14.90]			
LeBrun et al	3	7	1	40	1.0%	29.25 [2.43, 351.43]			
Lim et al	1	7	7	85	1.3%	1.86 [0.19, 17.69]			
Pass et al	32	123	214	3610	35.1%	5.58 [3.65, 8.54]		-	
Sobti et al	3	6	5	47	1.9%	8.40 [1.32, 53.40]			
Thakrar et al	4	12	1	6	1.1%	2.50 [0.21, 29.25]			
Wright et al	5	16	3	50	2.6%	7.12 [1.47, 34.39]			
Zajonz et al	5	12	16	299	4.1%	12.63 [3.61, 44.24]			
Total (95% CI)		446		6972	100.0%	7.75 [6.02, 9.97]		•	
Total events	132		370						
Heterogeneity: Tau ² =	0.00; Chi	² = 13.8	2, df = 14	(P = 0	.46); I ² = 0	0%	t		
Test for overall effect:	Z=15.91	(P < 0.	00001)				0.002	0.1 1 10 COVID-19 - COVID-19 +	500
<60 YEARS	COVID-	19 +	COVID-	19 -		Odds Ratio		Odds Ratio	
Study or Subgroup	Events		Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Fisher et al	2	10	1	24	100.0%	5.75 [0.46, 72.30]			
Total (95% CI)		10		24	100.0%	5.75 [0.46, 72.30]			
Total events	2		1						
Heterogeneity: Not ap	plicable						L	-t. tt.	
Test for overall effect:		P = 0.1	8)				0.01	0.1 1 10 COVID-19 - COVID-19 +	100

Fig. 5. Postoperative mortality in the patients with a mean age of (A) >60 years and (B) <60 years. M-

H, Mantel-Haenszel test; Random, random-effects model; CI, confidence interval.

erer't

VTE	COVID-	19 +	COVID	19 -		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Dallari et al	0	53	2	424	15.5%	1.58 [0.07, 33.34]			
Egol et al	2	17	3	107	41.3%	4.62 [0.71, 29.97]			
Fisher et al	2	10	0	24	14.7%	14.41 [0.63, 331.31]			
LeBrun et al	0	7	1	40	13.3%	1.76 [0.07, 47.33]			
Zajonz et al	0	12	2	299	15.1%	4.76 [0.22, 104.47]			_
Total (95% CI)		99		894	100.0%	4.08 [1.23, 13.58]		-	
Total events	4		8						
Heterogeneity: Tau ² =	= 0.00; Chi	² = 1.28	df = 4 (F	P = 0.86	i); l² = 0%		-		
Test for overall effect							0.005	0.1 1 10 COVID-19 - COVID-19 +	200

Fig. 6. Occurrence of venous thromboembolism in COVID-19-positive and -negative groups. M-H,

Mantel-Haenszel test; Random, random-effects model; CI, confidence interval.

Study period	Study design	Study location	Age (yr)	Female sex	Intervention location	Covid-19 (+)	(+) 6	Covid-19 (-)	(-) 6]	Follow- up
						Mortality	Total	Mortality	Total	di s
						(n=134, 29.38%)	surgery (n=456)	(n=371, 5.30%)	surgery (n=6,996)	
March 23, 2020-April 22, 2020 (1 mo)	Prospective	UK	60.7 (1–98)	88	Upper limb, hip, lower limb, and	4 (33.33)	12	4 (2.66)	150	Inpatient
March 26, 2020–May 20, 2020 (56 day)	Prospective	UK	65.0	Not reported	other trauma Clavicula, upper limb, hip, lower limb, and other	19 (44.18)	43	11 (7.53)	146	30-day
March 28, 2020–May 25, 2020 (59 day)	Prospective	UK	83.0 (76–90)	Not reported	trauma Proximal femur	9 (22.50)	40	8 (5.51)	145	Inpatient
March 1, 2020–April 19, 2020 (50 day)	Retrospective	Edinburg, UK	60.0 (14–102)	850	Upper limb, hip, lower limb, and other trauma	22 (32.35)	89	63 (4.19)	1,501	Inpatient
March 8, 2020-May 4, 2020 (58 day)	Retrospective	Italy	83.3	381	Hip	8 (15.09)	53	7 (1.65)	424	Inpatient
February 1, 2020–April 15, 2020 (75	Prospective	New York, USA	83.0	78	Hip	6 (35.29)	17	1 (0.93)	107	Inpatient
uay) March 16, 2020–May 15, 2020 (61 day)	Retrospective	New York, USA	58.0	10	Not reported	2 (20.0)	10	1 (4.16)	24	30-day
March 14, 2020–May 28, 2020 (76 day)	Cross-sectional	UK	81.6 (51-103)	Not reported	Hip	2 (40.0)	5	5 (5.95)	84	30-day
March 1, 2020–April 15, 2020 (46 day)	Retrospective	UK	80.0 (50-101)	Not reported	Hip	9 (36.0)	25	24 (8.63)	278	30-day
March 20, 2020–April 24, 2020 (36 day)	Retrospective	New York, USA	85.0 (65-100)	Not reported	Hip	3 (42.85)	7	1 (2.50)	40	Inpatient
March 1, 2020–May 15, 2020 (76 day) July 1, 2020–December 31, 2020 (6 mo)	Retrospective Retrospective	UK Germany, Austria, and Switzerland	84.9 85.0 (80–89)	70 2,678	Neck of femur Proximal femur	1 (14.28) 32 (26.01)	7 123	7 (8.23) 214 (0.61)	85 3,610	Inpatient Inpatient
March 1, 2020–May 31, 2020 (3 mo)	Prospective	UK	83.5	Not reported	Neck of femur	3 (50.0)	9	5 (10.63)	47	Inpatient
March 15, 2020-April 15, 2020 (1 mo)	Retrospective	UK	81.6 (54-100)	Not reported	Hip	4 (33.0)	12	1(16.60)	9	30-day
March 11, 2020–April 30, 2020 (41 day) Isanisry 1 2020–Isanisry 31 2021 (1 yr)	Retrospective Retrospective	UK Germany	81.1 (38–98) 82 0	Not reported	Neck of femur Provinal femur	5 (31.25) 5 (41.67)	1 19	3 (16.67) 16 (5 35)	50 200	30-day Innationt

Values are presented as mean (range), number only, or number (%).

l stay (day)	COVID-19 (-)	Not reported	Not reported	Not remorted	Not renorted	10.9	
Mean hospital stay (day)	COVID-19 (+)	Not reported	Not reported	Not		14.7	
Venous thromboembolism incidence	COVID-19 (-)	reported	Not reported	Not	Not	2	
Venous thror incic	COVID-19 (+)	Not reported	Not reported	Not	Not	0	
	Complication	Not reported	Not reported	Not reported	Not reported	138 Acute anemias 7 Pneumonias 8 Other respiratory omplications 9 AHFs 7 UTIs 2 ARFs 3 Sepsis 3 Sepsis 2 PEs 2 Letus cerebri 27 Other minor complications	
COVID-19 (-)	Underlying disease	1 COPD 2 Diabetes 1 Lung cancer 2 Stroke 1 Hypothyroidism 1 HD 1 HD 1 HC 1 CKD 1 AF	Not reported	Not reported	Not reported	Not reported	
	Primary cause of postoperative death	1 Pneumonia 1-1CH 1 sepsis 1 Record unavailable	1 Respiratory failure 1 Pneumonia 1 Old age 1 Sepsis 4 Records mavailable	Not reported	Not reported	Not reported	
	Complication	Not reported	Not reported	Not reported	Not reported	16 A cute anemias 6 Pneumonias 6 Oner respiratory complications 3 AHFs 2 UTIs 1 ARF	
COVID-19 (+)	Underlying disease	1 COPD 2 Diabetes 1 Lung cancer 1 Autoimmune disease 1 Prostate cancer 1 Lymphoma	Not reported	Not reported	Not reported	Not reported	
	Primary cause of postoperative death	4 Complications due to COVID-19	 5 Respiratory failures 2 Deliriums 1 Pneumonia 1 NOF fracture 	Not reported	Not reported	Not reported	
Total postoperative mortality		∞	17	30	85	15	
Study		Andrzejowski et al. [9]	Balakumar et al. [11]	Beaven et al. [10]	Clement et al. [12]	Dallari et al. [13]	

Ś	16.2	Not reported	Not reported 6
8	¢.	Not reported	Not reported 8
m	0	Not reported	reported 1
2	р	Not reported	reported 0
3 Sepsis 3 Sepsis 1 Bacterial pneumonia 3 PEs 3 MIs 2 Strokes 2 ARDSs 8 ARPs 6 UTB 3 5 Anemias 13 Hypotensions 12 AFs	 Cardiac arrest Postoperative anemias ARDS ARDS Pneumonia Sepsis UTI 	Not reported	Not reported 5 Pneumonias 7 UT 1 DVT 1 MI 2 Decubitus ulcers
40 Cardiovascular diseases (excluding hypertension) 67 Hypertensions 41 Immunocompromised states 20 Diabetes 38 Hyperlipidemias 27 Dementias	Not reported	Not reported	Not reported 1 CAD 1 AF 1 Hypertension 1 Hypethipidemia 1 Diabetes 1 Hypothyroidism 1 CKD
Not reported	Not reported	1 Complication from disseminated malignancy 1 UGIB 1 SUO 1 SCOO	Not reported 1 Intraoperative cardiac arrest
3 Sepsis 2 Bacterial pneumonias 10 Viral pneumonias 2 PEs 7 ARDSs 7 ARDSs 3 ARFs 3 AFFs 7 Aremias 7 Hypotensions 6 AFs	1 Cardiac arrest 5 Postoperative anemias 1 ARDS 2 PE/DVTs 2 PE/DVTs 2 Pneumonias 1 MI	Not reported	Not reported 6 Pneumonias 1 Arthythmia 2 UTIs
8 Cardiovascular diseases (excluding hypertension) 11 Hypertensions 11 Immocompromised atate 7 Diabetes 4 ARR's 9 Hyperlipidemias 6 Dementias	Not reported	Not reported	Not reported 3 Hypertensions 2 Hyperhipidemias 1 Osteoporosis 1 Malignancy 1 PUD 1 GERD 1 BPH
Not reported	Not reported	2 Complications due to COVID-19	9 Complications due to COVID-19 to COVID-19
٢	m	-	33
Egol et al. [14]	Fisher et al. [15]	Greensmith et al. [24]	Hall et al. [16] LeBrun et al. [17]

12	15.1	reported	10	S. 11				
30.3	19.1 I.91	ŻŻ	17	15.6	trial	dial	gin;	
	Post N	z z			se; AF, a	l, myocar	nown ori	ntestinal;
Not reported	Not reported		Not reported		ney disea	olism; MI	sis of unk	il, gastroi
Not reported	Not reported Not	reported	Not renorted	0	, chronic kid	nonary emb	;; SUO, sep	y disease; C
Not reported	Not reported	Not reported	Not reported	Not reported	disease; CKD,	ilure; PE, puln	stinal bleeding	coronary arter
5 Asthmas 6 CODbs 12 Other lung diseases 54 Cardiovascular diseases 30 Malignancies 14 Diabetes 19 Renal diseases 16 Dementias	Not reported	Not reported	Not reported	Not reported	COPD, chronic obstructive pulmonary disease; t-ICH, traumatic intracranial hemorrhage; IHD, ischemic heart disease; CKD, chronic kidney disease; AF, atrial	failure; UTI, urinary tract infection; ARF, acute renal failure; PE, pulmonary embolism; MI, myocardial	infarction; ARDS, acute respiratory distress syndrome; DVT, deep vein thrombosis; UGIB, upper gastrointestinal bleeding; SUO, sepsis of unknown origin;	PUD, peptic ulcer disease; GERD, gastrocsophageal reflux disease; BPH, benign prostatic hyperplasia; CAD, coronary artery disease; GI, gastrointestinal;
Not reported	Not reported	Not reported	Not reported	7 Cardiac decompensation with myocardial failures 2 PEs 2 Pneumonias 1 M1 1 Sepsis 1 Gl bleeding 1 Epileptic shock with aspiration 1 Henoic Alines	anial hemorrhage;	rry tract infection;	in thrombosis; UG	H, benign prostatio
Not reported	Not reported	Not reported	Not reported	Not reported	raumatic intracr	lure; UTI, urina	DVT, deep ve	flux disease; BF
1 Asthma 1 Other lung disease 5 Cardiovascular diseases 3 Malignancies 2 Diabetes 3 Renal diseases 3 Dementia	Not reported	Not reported	Not reported	Not reported	ry disease; t-ICH, t		distress syndrome;	astrocsophagcal re
1 Complication due to COVID-19	Not reported	4 Complications due	Not reported	5 Complications due to COVID-19	bstructive pulmona	fibrillation; NOF, neck of femur; AHF, acute heart	s, acute respiratory	r disease; GERD, g
œ	246 °	o vo	8	21), chronic ol	ation; NOF,	tion; ARDS	peptic ulce
Lim et al. [18]	Pass et al. [19]	Thakrar et al. [21]	Wright et al. [22]	Zajonz et al. [23]	COPD	fībrills	infarct	PUD,

Lor Lor Ver Ver Lor he interver	Carcoline	Anticipated absolute effect ^a (95% CI)	solute effect	OR (95% CI)	INO. OI participants	observational studies	evidence (GR ADF)
	I	Risk with COVID-19 (-) (per 100)	Risk with COVID-19 (+) (per 100)		500		
	Overall mortality	5	30 (25–36)	7.72 (6.01–9.93)	7,452	16	Low
	mortality	5	32 (24-41)	8.67 (5.82–12.91)	6,753	10	Low
	Postoperative mortality at 30- day follow-up	8	38 (26–51)	7.32 (4.30–12.49)	669	6	Very low ^{b)}
	Postoperative mortality in the patients with a mean age of >60 vr	5	30 (25–36)	7.75 (6.02–9.97)	7,418	15	Low
	Postoperative mortality in the patients with a mean age of <60 vr	4	20 (2–76)	5.75 (0.46–72.30)	34	1	Very low ^{c)}
	ance	П	4 (1–11)	4.08 (1.23–13.58)	993	5	Low
	RADE, Grading of Recommendat	tions, Assessment.	Development, and	Evaluation; CI, confie	dence interval; OR, odds	ratio.	
	The risk in the intervention group 5% CI). ^{b)} One study had a high ris		s based on the assu studies had modera	med risk in the compa te risk of bias. ^o The 9.	rison group and the relat 5% CI crosses the line of	ive effect of the in f no effect and has	ttervention (and its an insufficient

Table 3. GRADE summary of findings

ceem-22-403.pdf

ORIGINALITY REPORT



Exclude quotes On

Exclude bibliography On

Exclude matches < 2%